← Pulse/Companies/Compare
Apnimed
VS
Shionogi

Biotech comparison — funding, valuation, and investors, sourced from Value Add Pulse coverage.

A
Apnimed

Clinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.

3 Pulse stories
S
Shionogi

Japanese pharmaceutical company developing prescription drugs, infectious disease therapies, and specialty medicines, including a former sleep apnea drug joint venture with Apnimed.

2 Pulse stories
Total RaisedNot disclosed
Last ValuationNot disclosed
Biotech
Sector
Biotech
2017
Founded
1878
Cambridge, Massachusetts
HQ
Osaka, Japan
Public (APMD)
Status
Public (4507.T)
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Shionogi investors
No investors on record.

Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and Shionogi.